Option chain shows key data for Adastra Hldgs's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Adastra Hldgs.

Adastra Hldgs (OTC:XTXXF) Stock, Option Chain

Adastra Holdings Ltd is an extraction and processing solutions company. It aims to develop and deploy large-scale cannabis and hemp extraction technologies and provide turnkey processing solutions to help licensed standard and micro-cultivators maximize the value of every harvest. The company has two operating segments comprised of manufacturing and non-manufacturing operations. The manufacturing operations include the manufacturing, sale, and distribution of cannabis-related products, and the non-manufacturing operations include PerceiveMD.

Marijuana,Pot,Weed,Cannabis,Stock,Company,Business,Market,3d,Illustration, stock

Cannabis

Earnings

News

CSE:XTRX

XTXXF

Canadian Cannabis Concentrates Producer, Adastra, Reports Third Year Of Record Revenue, But Also Higher Losses

Markets

Candian marijuana operator Adastra Holdings Ltd. (OTC: XTXXF)(CSE:XTRX)(FRA:D2EP) reported Thursday financial results for the three months ended June 30, 2023, disclosing net revenue of CA$7.1 million, up by 132.68% year-over-year.

Canadian Marijuana Stock Posts 133% YoY Revenue Growth, But Also 124% Higher Net Loss In Q2

Penny Stocks

Cannabis producer Adastra Holdings Ltd. (CSE: XTRX) (FRA: D2EP) (OTC: XTXXF) reported on Tuesday financial results for the three months ended March 31, 2023.

Canadian Weed Company Adastra Reports Triple-Digit Q1 Revenue Growth, What&#39;s Behind The Figures?

ADASTRA HOLDINGS LTD by Adastra Holdings Ltd.

Adastra Holdings Ltd

AMST

Amesite Disclosed Nursemagic Enterprise Contract Wins In High Growth Companies With Hundreds Of Franchise Owners Across The Country

AGEN

Agenus Announced Five Presentations Featuring Botensilimab (Bot, An Fc-enhanced Anti-CTLA-4 Antibody) Plus Balstilimab (Bal, An Anti-PD-1 Antibody) At The Upcoming American Society Of Clinical Oncology Gastrointestinal Cancers Symposium

TKLF

CORRECTION: Tokyo Lifestyle Co H1 EPS $0.03 Down From $0.05 YoY, Sales $98.00M Up From $74.16M YoY

Draganfly's medical drone delivery infrastructure offers new model for future improvement in service time for Home Hospital care

DPRO

Draganfly Successfully Conducts Proof-Of-Concept Flights For Medical Drone Delivery With Mass General Brigham

Raymond James analyst Joseph Yanchunis initiates coverage on FinWise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FINW#NASDAQ">FINW</a>) with a Outperform rating and announces Price Target of $21.

Price Target

Initiation

Analyst Ratings

FINW

Raymond James Initiates Coverage On FinWise with Outperform Rating, Announces Price Target of $21

MESO

Mesoblast Announced Its Upcoming Addition To The Nasdaq Biotechnology Index As Part Of The Annual Reconstitution Of The 2024 Nasdaq Index

No dose-limiting toxicities were observed in the RAMP 203 first triplet combination cohort of avutometinib and LUMAKRAS&#x2122; (sotorasib) plus defactinib in patients previously treated with a G12C inhibitor

VSTM

Verastem Reports RAMP 203 Data: No Dose-Limiting Toxicities In Triplet Therapy For KRAS G12C NSCLC

Trading in the common shares and other listed securities of the Company on the Toronto Stock Exchange ("TSX") and the New York Stock Exchange (the "NYSE") has been halted.

Lion Electric Intends To Seek Recognition Of CCAA Proceedings In US Under Chapter 15 Of Bankruptcy Code; Files Application For Creditor Protection Under CCAA

WIIM

General Mills shares are trading lower after the company reported Q2 financial results and lowered FY25 adjusted EPS outlook.

CRVS

Corvus Pharmaceuticals Announced Interim Data From The Randomized, Double-blind, Placebo-controlled Phase 1 Clinical Trial Evaluating Soquelitinib In Patients With Moderate To Severe Atopic Dermatitis

Raymond James analyst Andrew Marok initiates coverage on DoubleVerify Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DV#NYSE">DV</a>) with a Outperform rating and announces Price Target of $25.

Raymond James Initiates Coverage On DoubleVerify Hldgs with Outperform Rating, Announces Price Target of $25

STRM

Streamline Health Solutions Announced That It Has Signed A New Contract For The Use Of RevID With A 400-bed, Oracle Health-EHR Based Health System With Facilities In Western Texas

Offerings

PESI

Perma-Fix Environmental Services Prices Public Offering Of 2.20M Shares Of Its Common Stock At $10.00 Per Share

Piper Sandler analyst John Barnidge upgrades Principal Finl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>) from Neutral to Overweight and maintains the price target from $90 to $90.

Upgrades

Piper Sandler Upgrades Principal Finl Gr to Overweight, Maintains Price Target to $90

Jefferies analyst Yaron Kinar downgrades RenaissanceRe Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNR#NYSE">RNR</a>) from Buy to Hold and lowers the price target from $304 to $282.

Downgrades

Jefferies Downgrades RenaissanceRe Holdings to Hold, Lowers Price Target to $282

General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) reported quarterly earnings of $1.40 per share which beat the analyst consensus estimate of $1.22 by 14.75 percent. This is a 12 percent increase over earnings of $1.25 per share from the same period last year. The company reported quarterly sales of $5.24 billion which beat the analyst consensus estimate of $5.14 billion by 1.94 percent. This is a 1.97 percent increase over sales of $5.14 billion the same period last year.

Earnings Beats

CORRECTION: General Mills Q2 2025 Adj EPS $1.40 Beats $1.22 Estimate, Sales $5.24B Beat $5.14B Estimate

PLRZ: 282% &#x7C; <a href="https://www.benzinga.com//node/42549301">Polyrizon Secures GMP Manufacturing Partnership With Eurofins CDMO Amatsiaquitaine, Advancing Toward PL-14 Allergy Blocker Clinical Trial In 2025</a>
&nbsp;
CRVS: 24% &#x7C; <a href="https://www.benzinga.com//node/42540476">Corvus Pharmaceuticals shares are trading higher after the company announced it will report on December 18 interim data from its Phase 1 clinical trial evaluating Soquelitinib in patients with moderate to severe atopic dermatitis.</a>
&nbsp;
OKLO: 10% &#x7C; <a href="https://www.benzinga.com//node/42550029">Oklo And Switch Partner To Deploy 12 GW Of Advanced Nuclear Power</a>

Movers

Trading Ideas

OKLO

PLRZ

Market-Moving News for December 18th

Janney Montgomery Scott analyst Robert Stevenson initiates coverage on Strawberry Fields REIT (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STRW#AMEX">STRW</a>) with a Buy rating.

STRW

Janney Montgomery Scott Initiates Coverage On Strawberry Fields REIT with Buy Rating

EV battery supplier and Tesla Inc. rival CATL has reportedly co-developed 10 new electric vehicle models with automakers that <a href="https://www.benzinga.com/markets/equities/24/08/40461793/nio-sets-the-stage-for-a-charging-revolution-reportedly-plans-massive-expansion-at-power-up-2024">use swappable batteries</a>.
What Happened: The first EV using CATL&#8217;s battery-swapping brand EVOGO&#8217;s &#8220;choco swap battery&#8221; will be rolled out this month, Reuters reported, citing the company&#8217;s CEO Yang Jun.
Yang was speaking at an event in the city of Xiamen, China. The remaining EVs co-developed by the company that uses swappable batteries will be launched in future months, the report added.
CATL is now looking to put up 1000 battery swapping stations in 2025. The swappable batteries would come in two standard sizes to accelerate adoption and the subscription fee for the choco swap battery swapping service would start from 369 yuan/ month, the report said.
As per Yang, China could eventually have enough battery-swapping stations to replace a third of its 100,000 gas stations. The executive also expects that battery swapping will make up a third of the options available to customers to fuel their electric vehicles such as home and public chargers by 2030.
Why It Matters: Chinese EV startup Nio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) is also a proponent of the <a href="https://www.benzinga.com/startups/23/11/35679384/nios-battery-swap-stations-could-overtake-teslas-superchargers-a-new-era-for-ev-convenience">battery-swapping technology</a>. The company opened its 2800th power swap station in China earlier this month.
The company also said earlier this month that it has completed over 60 million battery swaps and that nearly 60% of electricity powering Nio cars is provided through battery swapping. 
The company believes that power swapping can offer a recharging experience beyond refueling, particularly given the short wait time. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42546578/spacex-lost-ground-control-on-dragon-spacecraft-during-polaris-dawn-mission-due-to-power-outage-at-california-facility-report" target="_blank" rel="noreferrer noopener">SpaceX Lost Ground Control On Dragon Spacecraft During Polaris Dawn Mission Due To Power Outage At California Facility: Report</a></li>
</ul>
Photo courtesy: CATL

Tech

Tesla Rival CATL Co-Develops 10 EV Models With Battery Swap Technology: Report

CGTX

Cognition Therapeutics Reports Topline Results From Exploratory Phase 2 SHIMMER Study; Results Indicate Study Met Its Primary Endpoint Of Safety And Tolerability

Comments

Adastra Hldgs

Adastra Hldgs (XTXXF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga